Synthesis, anti-tobacco mosaic virus and cucumber mosaic virus activity, and 3D-QSAR study of novel 1,4-pentadien-3-one derivatives containing 4-thioquinazoline moiety

• Novel 1,4-pentadien-3-one derivatives containing 4-thioquinazoline moiety were designed and synthesized.
• The target compounds showed good antiviral activities against TMV and CMV.
• EC50 values of 7a were 124.3 and 365.5 μg/mL for the protection activity against TMV and CMV.
• EC50 value of 7j was 213.5 μg/mL for the curative activity against TMV.
• 3D-QSAR study was analyzed on the basis of the curative activity against TMV.

A series of novel 1,4-pentadien-3-one derivatives containing 4-thioquinazoline moiety were designed and synthesized. Antiviral bioassay results indicated that most of the title compounds exhibited excellent antiviral activities against tobacco mosaic virus (TMV) and cucumber mosaic virus (CMV) in vivo. Among the title compounds, 7j exhibited the best curative activity against TMV, with a half-maximal effective concentration (EC50) value of 213.5 μg/mL, which was better than that of ningnanmycin (270.9 μg/mL). Meanwhile, 7a showed remarkable protection activity against TMV and curative activity against CMV, with EC50 values of 124.3 and 365.5 μg/mL, respectively, which were superior to those of ningnanmycin (195.1 and 404.9 μg/mL, respectively). Comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) models were generated on the basis of the curative activities against TMV and exhibited good predictive abilities with cross-validated q2 and non-cross-validated r2 values for CoMFA and CoMSIA of 0.548, 0.647 and 0.994, 0.993, respectively. These results provided a practical tool for guiding the design and synthesis of novel and more potent 1,4-pentadien-3-one derivatives containing 4-thioquinazoline moiety.

Figure optionsDownload as PowerPoint slide